Cell Signaling Technology
XP Monoclonal Antibody

Product Pathways - Protein Folding

CDC37 (D11A3) XP® Rabbit mAb #4793

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP IF-IC H M R Mk Endogenous 50 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IF-IC=Immunofluorescence (Immunocytochemistry)
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

CDC37 (D11A3) XP® Rabbit mAb detects endogenous levels of total CDC37 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val297 of human CDC37 protein.

IF-IC

IF-IC

Confocal immunofluorescent analysis of HeLa cells, serum-starved (left) or EGF-treated (#8916, 100 ng/mL for 5 minutes; right), using CDC37 (D11A3) XP® Rabbit mAb (green). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).

Western blot analysis of extracts from various cell lines using CDC37 (D11A3) XP® Rabbit mAb.

Background

CDC37 is an important component of the HSP90 chaperone complex (1,2). It was initially identified for its involvement in cell-cycle progression and was later found to have a much broader role as a chaperone for a wide variety of kinases and other proteins (1-3). CDC37 protein has an amino-terminal kinase binding domain followed by a central HSP90 binding domain. It recruits and stabilizes kinases in the HSP90 complex by protecting the newly synthesized kinase peptide chain from degradation and promoting the next step of protein maturation (4,5). CDC37 also suppresses the ATPase activity of HSP90, thereby leading to conformational changes in the complex that preclude target kinase loading (6). CDC37 has been proposed as a therapeutic target because of its important role in multiple kinase pathways involved in proliferation and cancer cell survival, including Raf, Akt, Src, and ErbB2 pathways (7,8).

  1. Karnitz, L.M. and Felts, S.J. (2007) Sci STKE 2007, pe22.
  2. Caplan, A.J. et al. (2007) Trends Cell Biol 17, 87-92.
  3. Caplan, A.J. et al. (2007) Cell Cycle 6, 3145-7.
  4. Mandal, A.K. et al. (2007) J Cell Biol 176, 319-28.
  5. Lee, P. et al. (2002) J Cell Biol 159, 1051-9.
  6. Siligardi, G. et al. (2002) J Biol Chem 277, 20151-9.
  7. Kimura, Y. et al. (1997) Genes Dev 11, 1775-85.
  8. Gray, P.J. et al. (2008) Nat Rev Cancer 8, 491-5.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products